Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has granted inducement stock options to a new employee. The company awarded 130,000 options at an exercise price of $7.02 per share, matching the closing price on July 7, 2025.
The options, granted under Fulcrum's 2022 Inducement Stock Incentive Plan, have a ten-year term with a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.
Fulcrum Therapeutics (Nasdaq: FULC), una societ脿 biofarmaceutica in fase clinica, ha concesso opzioni azionarie di incentivo a un nuovo dipendente. L'azienda ha assegnato 130.000 opzioni a un prezzo di esercizio di 7,02$ per azione, corrispondente al prezzo di chiusura del 7 luglio 2025.
Le opzioni, concesse nell'ambito del Piano di Incentivazione Azionaria 2022 di Fulcrum, hanno una durata di dieci anni e un piano di maturazione quadriennale. La maturazione prevede un 25% dopo il primo anno e un 6,25% ogni trimestre nei tre anni successivi, subordinata alla continuazione del rapporto di lavoro.
Fulcrum Therapeutics (Nasdaq: FULC), una compa帽铆a biofarmac茅utica en etapa cl铆nica, ha otorgado opciones sobre acciones como incentivo a un nuevo empleado. La empresa concedi贸 130,000 opciones a un precio de ejercicio de $7.02 por acci贸n, igualando el precio de cierre del 7 de julio de 2025.
Las opciones, otorgadas bajo el Plan de Incentivos de Acciones 2022 de Fulcrum, tienen un plazo de diez a帽os con un calendario de adquisici贸n de derechos de cuatro a帽os. La adquisici贸n incluye un 25% despu茅s del primer a帽o y un 6.25% trimestral durante los siguientes tres a帽os, condicionado a la continuidad del empleo.
Fulcrum Therapeutics (雮橃姢雼�: FULC)電� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 鞁犾瀰 歆侅洂鞐愱矊 鞙犾澑 欤检嫕 鞓奠厴鞚� 攵�鞐枅鞀惦媹雼�. 須岇偓電� 2025雲� 7鞗� 7鞚� 膦呹皜鞕� 霃欖澕頃� 欤茧嫻 7.02雼煬鞚� 頄夓偓臧�瓴╈溂搿� 130,000欤� 鞓奠厴鞚� 靾橃棳頄堨姷雼堧嫟.
鞚� 鞓奠厴鞚� Fulcrum鞚� 2022雲� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 攵�鞐悩鞐堨溂氅�, 10雲� 毵岅赴鞐� 4雲勱皠 氩犾姢韺� 鞚检爼鞚� 鞝侅毄霅╇媹雼�. 氩犾姢韺呾潃 觳� 頃� 頉� 25%鞕� 鞚错泟 3雲� 霃欖晥 攵勱赴氤� 6.25%臧� 瓿勳啀 攴茧 臁瓣贝 頃橃棎 鞚措（鞏挫雼堧嫟.
Fulcrum Therapeutics (Nasdaq : FULC), une soci茅t茅 biopharmaceutique en phase clinique, a accord茅 des options d'achat d'actions incitatives 脿 un nouvel employ茅. La soci茅t茅 a attribu茅 130 000 options 脿 un prix d'exercice de 7,02 $ par action, correspondant au cours de cl么ture du 7 juillet 2025.
Les options, accord茅es dans le cadre du Plan d'Incitation 脿 l'Attribution d'Actions 2022 de Fulcrum, ont une dur茅e de dix ans avec un calendrier d'acquisition des droits sur quatre ans. L'acquisition comprend 25 % apr猫s la premi猫re ann茅e et 6,25 % trimestriellement au cours des trois ann茅es suivantes, sous r茅serve de la poursuite de l'emploi.
Fulcrum Therapeutics (Nasdaq: FULC), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat einem neuen Mitarbeiter Anreiz-Aktienoptionen gew盲hrt. Das Unternehmen vergab 130.000 Optionen zu einem Aus眉bungspreis von 7,02 $ pro Aktie, entsprechend dem Schlusskurs vom 7. Juli 2025.
Die Optionen wurden im Rahmen des Fulcrum Inducement Stock Incentive Plans 2022 gew盲hrt und haben eine Laufzeit von zehn Jahren mit einem vierj盲hrigen Vesting-Zeitplan. Das Vesting umfasst 25 % nach dem ersten Jahr und viertelj盲hrlich 6,25 % 眉ber die folgenden drei Jahre, vorausgesetzt die Besch盲ftigung wird fortgesetzt.
- None.
- None.
CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.庐 (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company鈥檚 common stock pursuant to the company鈥檚 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum granted the new employee 130,000 options to purchase shares of the company鈥檚 common stock at an exercise price of
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum鈥檚 lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
617-283-2856
FAQ
What stock options did Fulcrum Therapeutics (FULC) grant to its new employee?
What is the vesting schedule for FULC's new employee stock options?
When were the Fulcrum Therapeutics (FULC) inducement grants approved?
What is the purpose of Fulcrum's inducement stock option grants?
